Background The optimal timing of radiotherapy after radical prostatectomy for prostate cancer
is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy versus …

Background Metastatic castration-resistant prostate cancers are enriched for DNA repair
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …

Active surveillance (AS) has been introduced as an observational strategy to delay or avoid
curative treatment without compromising long‐term cancer‐specific survival. The 10 studies …

… Financial disclosures: Klaus Brasso certifies that all conflicts of interest, including specific …
, or pending), are the following: Klaus Brasso received consulting fees from Astellas, Bayer AG, …

Objective To study short-term (<90 days) morbidity and mortality following radical cystectomy
(RC) for bladder cancer and identify modifiable risk factors associated with these. Design …

Androgen deprivation therapy ( ADT ) remains a cornerstone in the management of patients
with prostate cancer ( PCa ) despite adverse effects on body composition and functional …

A first-in-human clinical trial with Positron Emission Tomography (PET) imaging of the
urokinase-type plasminogen activator receptor (uPAR) in patients with breast, prostate and …

BACKGROUND To examine the prognostic value of markers of bone metabolism (serum
PINP, BAP, and CTX‐I) and serum YKL‐40 in metastatic prostate carcinoma (PC). METHODS …

Purpose Increasing evidence indicates that statin use may reduce mortality from prostate
cancer. In this work, we examined whether postdiagnosis statin use was associated with …

The impact of cytoreductive radical prostatectomy (CRP) on oncological outcomes in
patients with prostate cancer (PCa) and distant metastases has been demonstrated by …